| Meta-analysis summary statistics for associations meeting genome-wide significance | |||||||
|---|---|---|---|---|---|---|---|
| Lead SNP | Biochemicals | EA/OA | Ntotal | EAF | Effect (SE) | Pmeta | Details |
| rs1934963 | X-11787 | T/C | 7362 | 0.8 | 0.029 (0.002) | 8.69·10-65 | show |
EA = effect allele; OA = other allele; EAF = frequency of effect allele;
| Summary of biological annotations | |
|---|---|
| SNP | rs1934963 |
| Chromosomal location | Chr10: 96,724,666 (10q23.33) |
| Gene (distance) | CYP2C9 (0) |
| Predicted causal gene | unknown |
| Gene/protein classification | metabolic enzyme |
| Metabolite (Pathway) | X-11787 (Unknown) |
| Biochemical locus-metabolite relationship | X-11787 is an unknown metabolite |
| eQTL associations | - |
| Medical information | |
|---|---|
| Complex trait associations | Warfarin maintenance dose [18535201] |
| Known metabolite associations | X-11787 [23093944] (r2=0.308 with rs7896133) |
| Inborn error of metabolism | - |
| Pharmacological information | |
|---|---|
| ChEMBL ID | CHEMBL3397 |
| Drug information | Substrates: NSAIDs (e.g. diclofenac, celecoxib, ibuprofen, flurbiprofen, naproxen, piroxi- cam, mefenamic acid, and suprofen), oral hypoglycemics (e.g., glyburide, glipizide, glimepiride, tolbutamide), oral anticoagulants (e.g., S-warfarin, S-acenocoumarol, and phenprocoumon), diuretics and uricosurics (e.g., sulfinpyrazone sulfide, torsemide, tienilic acid ticrynafen), angiotensin II blockers (e.g., candesartan, irbesartan, losartan), anticonvulsants (e.g., phenytoin), and many others; Inhibitors: Tienilic acid, benzbromarone and 2-methyl- 3-(3',5'-diiodo-4'-hydroxybenzoyl)benzoflura, amiodarone, capecitabine, fluconazole, fluoxetine, fluvoxamine, oxandrolone, sulfaphenazole, sulfinpyrazone |
| Locus information for top associated metabolite | |
|---|---|
HapMap2 imputation![]() | 1KGP imputation![]() |








